Company Profile
DBV Technologies Stock Price, News & Catalysts
- Ticker:
- DBVT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France
Stock performance
11.21 USD (-4.68%)
Close
Last updated: October 1, 2026
1.08B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, DBVT closed down 4.68% at $11.21. No new same-company headline was identified in the current news window.
Company overview
Food-Allergy Immunotherapy Company
DBV Technologies is developing treatments for food allergy using epicutaneous immunotherapy. Its programs are designed to deliver small quantities of allergen through intact skin with the goal of desensitizing patients while limiting systemic exposure.
Viaskin Patch Platform
The Viaskin patch places allergen on the skin, where it is taken up by immune cells without requiring an injection or oral dose. The approach is intended to offer a convenient, non-invasive treatment format suitable for young children.
Viaskin Peanut in Children
The lead program, Viaskin Peanut, is being developed for peanut-allergic children aged four through seven years. The registration package is supported by the pivotal Phase 3 VITESSE study and is being prepared for U.S. regulatory submission.
Toddler and Infant Development
DBV is extending Viaskin Peanut into younger age groups through the COMFORT Toddlers safety study in children aged one through three years and the THRIVE study in peanut-allergic infants aged six through twelve months. This lifecycle strategy could broaden the addressable population across early childhood.
Allergy-Specialist Commercial Model
If approved, Viaskin Peanut would be marketed through allergists and other specialists who manage pediatric food allergy. DBV is building U.S. medical, safety, regulatory, supply-chain, and commercial capabilities while producing pre-commercial inventory.
Future catalysts
- U.S. BLA submission for Viaskin Peanut in children aged four through seven years in the third quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of DBV Technologies (DBVT)?
DBV Technologies (DBVT) most recently closed at 11.21 USD, a -4.68% move versus the previous session.
What is the market cap of DBV Technologies (DBVT)?
DBV Technologies currently has a market capitalization of 1.08B USD on BioPharmSignal.
What does DBV Technologies do?
Food-Allergy Immunotherapy Company DBV Technologies is developing treatments for food allergy using epicutaneous immunotherapy. Its programs are designed to deliver small quantities of allergen through intact skin with the goal of desensitizing patients while limiting systemic exposure. Viaskin Patch Platform The Viaskin patch places allergen on the skin,...
On which exchange is DBVT stock listed?
DBV Technologies (DBVT) is associated with NASDAQ, France, Biopharma.
What is Food-Allergy?
Food-Allergy Immunotherapy Company DBV Technologies is developing treatments for food allergy using epicutaneous immunotherapy.
Which conditions is DBV Technologies targeting with Food-Allergy?
Food-Allergy Immunotherapy Company DBV Technologies is developing treatments for food allergy using epicutaneous immunotherapy. Its programs are designed to deliver small quantities of allergen through intact skin with the goal of desensitizing patients while limiting systemic exposure. Viaskin Patch Platform The Viaskin patch places allergen on the skin,...
How does DBV Technologies describe recent progress with Food-Allergy?
U.S. BLA submission for Viaskin Peanut in children aged four through seven years in the third quarter of 2026.
What is Immunotherapy?
Food-Allergy Immunotherapy Company DBV Technologies is developing treatments for food allergy using epicutaneous immunotherapy.